Optimising percutaneous valve-in-valve TAVI with bioprosthetic valve fracture-Reference-Cited by-同舟云学术

Optimising percutaneous valve-in-valve TAVI with bioprosthetic valve fracture

Published:2024-05-28 Issue:5 Volume:53 Page:328-330
ISSN:0304-4602
Container-title:Annals of the Academy of Medicine, Singapore
language:en
Short-container-title:Ann Acad Med Singap

Author:

Chiam Paul TL¹,Nair Dinesh¹,Lim Yean Teng¹,Sivathasan Cumaraswamy¹

Affiliation:

1. Mount Elizabeth Hospital, Singapore

Abstract

Percutaneous transcatheter aortic valve implantation (TAVI) has become an established therapy for inoperable patients, for high, intermediate and low surgical-risk patients over 65 years old with severe aortic valve stenosis (AS).1,2 Valve-in-valve (ViV) TAVI is an approved indication for patients with degenerated aortic surgical bioprostheses.

Publisher

Academy of Medicine, Singapore

Reference10 articles.

1. Chiam PTL. Transcatheter aortic valve implantation in Asia: the first decade. EuroIntervention 2018;14:35-7.

2. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021;143:e72-e227.

3. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. JAMA 2014;312:162-70.

4. Webb JG, Murdoch DJ, Alu MC, et al. 3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses. J Am Coll Cardiol 2019;73:2647-55.

5. Chiam P, Ewe S, Soon J, et al. Percutaneous transcatheter aortic valve implantation for degenerated surgical bioprostheses: the first case series in Asia with one-year follow-up. Singapore Med J 2016;57:401-5.